---
figid: PMC2785127__nihms66493f5
figlink: /pmc/articles/PMC2785127/figure/F5/
number: Figure 5
caption: 'Putative targets of common changes in gene expression with single and repeated
  IMO stress. Pathway analysis showing the common targets which are activated or inhibited
  by the common genes which are decreased (green, IL15, MMP14, CXCR4) or elevated
  (pink, all others) or by both durations of IMO stress. The symbols are as described
  in figure above. The abbreviations are as follows: PARP1 [ADP-ribosyltransferase
  (NAD+; poly (ADP-ribose) polymerase)]; BCL2 (B-cell leukemia/lymphoma 2); BCL2L1
  (Bcl2-like 1); BDKRB2 (bradykinin receptor B2); BDNF (brain-derived neurotrophic
  factor); CALCA (calcitonin/calcitonin-related polypeptide, alpha); CREB1 (cAMP responsive
  element binding protein 1); CASP3 (caspase 3); CD44 (CD44 antigen); CCK (cholecystokinin);
  EGR1 (early growth response 1); EGF (epidermal growth factor); EGFR (epidermal growth
  factor) FOS (FOS oncogene); GAL (galanin); GNRH1 (gonadotropin-releasing hormone
  1); GRB2 (growth factor receptor bound protein 2); IER2 (immediate early response
  2); INS (insulin); IRS1 (insulin receptor substrate 1); IGF1 (insulin-like growth
  factor 1); IFNG (interferon, gamma); IL15 (interleukin 15); IL4R (interleukin 4
  receptor); JUN (Jun oncogene); MMP14 (matrix metalloproteinase 14); MMP9 (matrix
  metalloproteinase 9); MAPK1 (mitogen activated protein kinase 1); MAPK3 (mitogen
  activated protein kinase 3); MAP2K1 (mitogen activated protein kinase kinase 1);
  RAF1 (murine leukemia viral oncogene homolog 1); NGFR (nerve growth factor receptor);
  NMU (neuromedin U); NPY (neuropeptide Y); NTF5 (neurotrophin 5); NOS1 (nitric oxide
  synthase 1); NFIL3 (nuclear factor, interleukin 3 regulated); NR4A1 (nuclear receptor
  subfamily 4, group A, member 1); NR4A2 (nuclear receptor subfamily 4, group A, member
  2); NR4A3 (nuclear receptor subfamily 4, group A, member 3); PARG [poly (ADP-ribose)
  glycohydrolase]; POMC (proopiomelanocortin); PDP2 (pyruvate dehydrogenase phosphatase
  isoenzyme 2); SST (somatostatin); SHC1 (src homology 2 domain-containing transforming
  protein C1); SYN1 (synapsin I); TAC1 (tachykinin, precursor 1); THBD (thrombomodulin);
  AKT1 (thymoma viral proto-oncogene 1); TRH (thyrotropin-releasing hormone); TGFB1
  (transforming growth factor, beta 1); TNF (tumor necrosis factor); TH (tyrosine
  hydroxylase); UTS2 (urotensin 2); VEGF (vascular endothelial growth factor); VIP
  (vasoactive intestinal peptide); VGF (VGF nerve growth factor inducible).'
pmcid: PMC2785127
papertitle: Identifying the Stress Transcriptome in the Adrenal Medulla Following
  Acute and Repeated Immobilization.
reftext: Xiaoping Liu, et al. Ann N Y Acad Sci. ;1148:1-28.
pmc_ranked_result_index: '234876'
pathway_score: 0.8753556
filename: nihms66493f5.jpg
figtitle: Putative targets of common changes in gene expression with single and repeated
  IMO stress
year: ''
organisms: Homo sapiens
ndex: 10cd1cf8-df1b-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2785127__nihms66493f5.html
  '@type': Dataset
  description: 'Putative targets of common changes in gene expression with single
    and repeated IMO stress. Pathway analysis showing the common targets which are
    activated or inhibited by the common genes which are decreased (green, IL15, MMP14,
    CXCR4) or elevated (pink, all others) or by both durations of IMO stress. The
    symbols are as described in figure above. The abbreviations are as follows: PARP1
    [ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase)]; BCL2 (B-cell leukemia/lymphoma
    2); BCL2L1 (Bcl2-like 1); BDKRB2 (bradykinin receptor B2); BDNF (brain-derived
    neurotrophic factor); CALCA (calcitonin/calcitonin-related polypeptide, alpha);
    CREB1 (cAMP responsive element binding protein 1); CASP3 (caspase 3); CD44 (CD44
    antigen); CCK (cholecystokinin); EGR1 (early growth response 1); EGF (epidermal
    growth factor); EGFR (epidermal growth factor) FOS (FOS oncogene); GAL (galanin);
    GNRH1 (gonadotropin-releasing hormone 1); GRB2 (growth factor receptor bound protein
    2); IER2 (immediate early response 2); INS (insulin); IRS1 (insulin receptor substrate
    1); IGF1 (insulin-like growth factor 1); IFNG (interferon, gamma); IL15 (interleukin
    15); IL4R (interleukin 4 receptor); JUN (Jun oncogene); MMP14 (matrix metalloproteinase
    14); MMP9 (matrix metalloproteinase 9); MAPK1 (mitogen activated protein kinase
    1); MAPK3 (mitogen activated protein kinase 3); MAP2K1 (mitogen activated protein
    kinase kinase 1); RAF1 (murine leukemia viral oncogene homolog 1); NGFR (nerve
    growth factor receptor); NMU (neuromedin U); NPY (neuropeptide Y); NTF5 (neurotrophin
    5); NOS1 (nitric oxide synthase 1); NFIL3 (nuclear factor, interleukin 3 regulated);
    NR4A1 (nuclear receptor subfamily 4, group A, member 1); NR4A2 (nuclear receptor
    subfamily 4, group A, member 2); NR4A3 (nuclear receptor subfamily 4, group A,
    member 3); PARG [poly (ADP-ribose) glycohydrolase]; POMC (proopiomelanocortin);
    PDP2 (pyruvate dehydrogenase phosphatase isoenzyme 2); SST (somatostatin); SHC1
    (src homology 2 domain-containing transforming protein C1); SYN1 (synapsin I);
    TAC1 (tachykinin, precursor 1); THBD (thrombomodulin); AKT1 (thymoma viral proto-oncogene
    1); TRH (thyrotropin-releasing hormone); TGFB1 (transforming growth factor, beta
    1); TNF (tumor necrosis factor); TH (tyrosine hydroxylase); UTS2 (urotensin 2);
    VEGF (vascular endothelial growth factor); VIP (vasoactive intestinal peptide);
    VGF (VGF nerve growth factor inducible).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PARP6
  - PARP16
  - PARP2
  - PARG
  - PARP3
  - PARP1
  - PARP11
  - FOS
  - PARP4
  - PARP15
  - PARP8
  - TNKS2
  - TH
  - PARP9
  - TIPARP
  - PARP14
  - TNKS
  - PARP12
  - PARP10
genes:
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP6
  entrez: '56965'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP16
  entrez: '54956'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP2
  entrez: '10038'
- word: (PARG
  symbol: PARG
  source: hgnc_symbol
  hgnc_symbol: PARG
  entrez: '8505'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP3
  entrez: '10039'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP1
  entrez: '142'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP11
  entrez: '57097'
- word: Fos
  symbol: FOS
  source: hgnc_symbol
  hgnc_symbol: FOS
  entrez: '2353'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP4
  entrez: '143'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP15
  entrez: '165631'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP8
  entrez: '79668'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: TNKS2
  entrez: '80351'
- word: TH
  symbol: TH
  source: hgnc_symbol
  hgnc_symbol: TH
  entrez: '7054'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP9
  entrez: '83666'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: TIPARP
  entrez: '25976'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP14
  entrez: '54625'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: TNKS
  entrez: '8658'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP12
  entrez: '64761'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP10
  entrez: '84875'
chemicals: []
diseases: []
---
